ArticleCureus2025
Usefulness of Four-Point Dermal-Injection Lymphatic Scintigraphy for Lower-Limb Lymphedema.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLymphatic scintigraphy using radioisotope agents is a good method for evaluating the lymph flow status of patients with lower-limb lymphedema. To depict wide regions of lower-limb lymphatic vessels, at our institution, we administer radioisotopes at four locations in each limb when lymphatic scintigraphy images are to be obtained. Herein, we evaluated the correlation of lymphatic scintigraphy with lymphedema staging and investigated the usefulness of this four-point dermal-injection lymphatic scintigraphy (LyS4). MATERIALS AND
methodsThe 52 lower limbs of 26 patients (23 females, three males, aged 20-85 years, median 65 years) underwent a LyS4 examination of their lower limbs. The stage of lower-limb lymphedema was diagnosed by plastic surgeons at our institution using the International Society of Lymphology (ISL) staging system. The patients' ISL stages were stage 0 (n=20), stage 1 (n=7), and stage 2 (n=25). No patient was stage 3. For each LyS4 examination, technetium-99m human serum albumin diethylenetriamine pentaacetic acid (99mTc-HSA) was injected. The four injection points were the first interdigital web, slightly below the area of the lateral malleolus, slightly below the area of the medial malleolus, and the lateral side of the feet near the fifth digit of both feet. Using the planar LyS4 images, we investigated the positive/negative appearance of the four lymphatic vessel regions, i.e., anteromedial (AM), anterolateral (AL), posteromedial (PM), and posterolateral (PL) and the dermal backflow (DB). We then examined the correlations of these parameters with the ISL stage.
resultsThe absence of AM, the absence of PM, the appearance of DB, and the number of lymphatic vessels depicted were each significant factors for distinguishing lymphedema. The appearance of DB and the number of lymphatic vessels depicted can distinguish moderate lymphedema (ISL stage 0 or 1) from severe lymphedema (ISL stage 2e or 2d). Regarding the diagnostic performance of the LyS4 parameters, high accuracy was observed for the appearance of PM (0.71), that of DB (0.79), and the number of depicted lymphatic vessels (0.77).
conclusionLyS4 is a useful method with good correlation with the ISL stage in patients with lower-limb lymphedema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.